Gut molecule research could help control glucose levels 29 January 2018 Most of us know that insulin plays an important role in removing excess glucose from the blood, but did you know it isn’t the only molecule involved in the process? Another molecule that plays a role is glucagon-like peptide-1 (GLP-1). Now Professor Marco Falasca and his team from Curtin University, with the support of Diabetes Australia, are investigating ways of increasing the amount of GLP-1 somebody produces and whether that can help control glucose levels. “We know GLP-1 is released in the gut when people eat. It has a key role to play in regulating blood glucose levels,” Professor Falasca said. “We also know that people with diabetes have a decreased ability to release GLP-1, so what we want to do it find a way of increasing the body’s production of the molecule. “Researchers have tried to produce drugs that mimic GLP-1 but they haven’t been too successful so we are trying a different approach. “There is a compound in the body, belonging to the lipid family, which stimulates the release and production of GLP-1. What we are trying to do is determine if this lipid, or molecules similar to it, can be used to stimulate the production of GLP-1. “Hopefully, if we are successful, this could lead to a new therapy for supporting people with diabetes.” If you are interested in helping Diabetes Australia support research like this you can find out more here.
Media releases 18 November 2026 Foundayo approval a welcome addition to GLP-1 treatment options Diabetes Australia has welcomed the TGA approval of Foundayo (orforglipron), a new oral GLP-1 receptor agonist for the management of type 2 diabetes and chronic weight management in eligible adults. Continue Reading
Media releases 6 November 2026 Diabetes Australia welcomes new oral GLP-1 treatment option for Australians Diabetes Australia welcomes the Therapeutic Goods Administration’s (TGA) recent approval of a new oral formulation of Wegovy (semaglutide) as a step forward in the treatment of obesity and related chronic conditions. Continue Reading
News 24 July 2026 GLP-1 RA safety update for rare but severe eye disorders The Therapeutic Goods Administration has updated GLP-1 RA product warnings because of their potential to cause a rare but severe eye disorder. The glucagon-like peptide-1 receptor agonist... Continue Reading